梅尔法兰
医学
粘膜炎
队列
多发性骨髓瘤
内科学
外科
移植
不利影响
回顾性队列研究
胃肠病学
肿瘤科
化疗
作者
Lalit Kumar,Ranjit Kumar Sahoo,Sudhir Kumar,Annie K. Baa,Ghazal Tansir,Neha Pathak,Prabhat S. Malik,Om Dutt Sharma,Anisha Mathew,Ankit Jha,Ritu Gupta,Atul Sharma,Ahitagni Biswas,Rakesh Kumar,Sanjay Thulkar,Soumyaranjan Malik,Ashish Dutt
标识
DOI:10.1080/10428194.2022.2148214
摘要
We evaluated impact of melphalan dose on transplant outcomes for multiple myeloma. Between 1995 and 2019 459 consecutive patients received a transplant; 69(15%) received melphalan ≤150 mg/m2 (Mel 150 cohort) and 390 (85%) melphalan 200 mg/m2 (MEL 200 cohort). The primary outcome was overall survival (OS) from the date of transplant. Progression-free survival (PFS), engraftment, transplant response, and cumulative relapse at 2 years were secondary outcome measures. Patients in Mel 150 cohort had adverse clinical and laboratory parameters at base line. Transplant response was better for Mel 200 cohort (p < 0.024). Median OS at a median follow-up of 88 months was similar in the two cohorts; 100 Vs 102 months (Mel 200), p = 0.817. Median PFS (60.0 Vs 53 months, p = 0.746), relapse at two years (32.4% Vs 30.9%, p = 0.745) and grade 3-4 mucositis (p = 0.823) were similar. Initial treatment prepares patients better for subsequent similar transplant outcomes despite differences in baseline characteristics.
科研通智能强力驱动
Strongly Powered by AbleSci AI